Systen 50

DRUG3 trials

Sponsors

Amsterdam UMC, Amsterdam UMC Stichting

Conditions

(peri) MenopauseClimacteric symptomsDiabetes MellitusInsomniaTransgender women using long-term gender-affirming hormone therapy

Phase 4

Short-term changes in cardiovascular risk determinants after temporarily stopping gender-affirming hormone therapy in older transgender women - a pilot study

CompletedCTIS2023-505143-39-00

Amsterdam UMCTransgender women using long-term gender-affirming hormone therapy

Start: 2024-02-23End: 2025-09-29Target: 30Updated: 2023-09-15

The role of online sleep intervention and hormone therapy on sleep, climacteric symptoms and mood in the perimenopause

RecruitingCTIS2024-512071-12-00

Amsterdam UMC StichtingClimacteric symptoms, Insomnia

Start: 2025-10-29Target: 222Updated: 2025-10-22

The effect of transdermal 17-β-estradiol/progesterone supplementation on glucose regulation in peri- and postmenopausal women with type 1 and type 2 diabetes

Not yet recruitingCTIS2025-523214-83-00

Amsterdam UMC StichtingDiabetes Mellitus, (peri) Menopause

Target: 48Updated: 2025-12-15